CN115003332A - 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途 - Google Patents

抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途 Download PDF

Info

Publication number
CN115003332A
CN115003332A CN202180008488.0A CN202180008488A CN115003332A CN 115003332 A CN115003332 A CN 115003332A CN 202180008488 A CN202180008488 A CN 202180008488A CN 115003332 A CN115003332 A CN 115003332A
Authority
CN
China
Prior art keywords
cancer
antibody
seq
furoquintinib
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180008488.0A
Other languages
English (en)
Inventor
闫洪滨
王斯斯
谢帆
戴秋曦
陈文会
王倩
郭倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENOR BIOPHARMA CO Ltd
Hutchmed Ltd
Original Assignee
GENOR BIOPHARMA CO Ltd
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENOR BIOPHARMA CO Ltd, Hutchison Medipharma Ltd filed Critical GENOR BIOPHARMA CO Ltd
Publication of CN115003332A publication Critical patent/CN115003332A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

抗PD‑1抗体或其抗原结合片段与呋喹替尼或其药学上可接受的盐联合在制备治疗癌症的药物中的用途。抗PD‑1抗体与呋喹替尼联合用药具有一定的协同作用，与相应的单独用药相比，抑制肿瘤生长的效果明显，给药期间，实验动物耐受性良好，未见不良反应。

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN202180008488.0A 2020-01-17 2021-01-15 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途 Pending CN115003332A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010052280.6A CN113134080A (zh) 2020-01-17 2020-01-17 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途
CN2020100522806 2020-01-17
PCT/CN2021/071996 WO2021143799A1 (zh) 2020-01-17 2021-01-15 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途

Publications (1)

Publication Number Publication Date
CN115003332A true CN115003332A (zh) 2022-09-02

Family

ID=76808365

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010052280.6A Pending CN113134080A (zh) 2020-01-17 2020-01-17 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途
CN202180008488.0A Pending CN115003332A (zh) 2020-01-17 2021-01-15 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010052280.6A Pending CN113134080A (zh) 2020-01-17 2020-01-17 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途

Country Status (2)

Country Link
CN (2) CN113134080A (zh)
WO (1) WO2021143799A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114159557B (zh) * 2021-11-09 2024-07-19 北京东方百泰生物科技股份有限公司 一种治疗肿瘤疾病的联合用药组合物及应用
CN118660720A (zh) * 2022-02-22 2024-09-17 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201900571YA (en) * 2014-07-22 2019-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
TWI764943B (zh) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
CN111065411B (zh) * 2017-11-16 2023-03-10 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
CN110624106A (zh) * 2018-06-22 2019-12-31 嘉和生物药业有限公司 Pd-1信号通路拮抗剂与艾滋病疫苗的联合应用
CN112043702A (zh) * 2019-06-05 2020-12-08 正大天晴药业集团股份有限公司 用于联合治疗结直肠癌的喹啉类化合物

Also Published As

Publication number Publication date
WO2021143799A1 (zh) 2021-07-22
CN113134080A (zh) 2021-07-20

Similar Documents

Publication Publication Date Title
RU2762746C2 (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
TWI744617B (zh) 治療潰瘍性結腸炎之方法
AU2009210656A1 (en) Use of picoplatin and cetuximab to treat colorectal cancer
US20120128670A1 (en) mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
TWI818120B (zh) 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療
JP2019510785A (ja) 癌を処置する方法
CN113613674A (zh) 治疗小细胞肺癌的联用药物组合物
JP2024154382A (ja) Ａｂｃｂ５のリガンドおよび基質
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN115003332A (zh) 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途
CN113018429A (zh) 治疗卵巢癌的药物组合
TW202346342A (zh) 抗tim-3抗體與抗pd-1抗體的藥物組合
WO2020239085A1 (zh) 治疗黑色素瘤的联用药物组合物
EP4159238A1 (en) Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody
CN116437957A (zh) 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物
CN112915202A (zh) 喹啉衍生物与pd-1单抗的药物组合
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
RU2802962C2 (ru) Композиции и способы лечения рака печени
CN115779095A (zh) 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
WO2023111810A1 (en) Combination therapies and uses for treating cancer
AU2021382148A9 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN118159538A (zh) 含met受体酪氨酸激酶抑制剂的药物组合及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination